top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Arnold Baskies Biography and Net Worth

Director of Baudax Bio

Dr. Arnold Baskies has served as director since August 2020. From 2007 to 2010, Dr. Baskies served as the Chief Medical Officer for the American Cancer Society of New York and New Jersey, as well as sitting on the Executive Committee and the Board of Directors and was elected as President of the American Cancer Society for New York and New Jersey in September 2010. Dr. Baskies is the recipient of major awards in cancer research from the Society of Surgical Oncology, the American Radium Society, the Society of Head and Neck Surgeons, and the American Cancer Society. In addition, Dr. Baskies has received the EPIC Award from the NJ Institute of Nursing and the Silver Chalice Award from the American Cancer Society, for his role in providing leadership in cancer prevention and treatment for the citizens of New Jersey. Dr. Baskies has maintained a medical practice in southern New Jersey for 37 years, as well as holding major state and national leadership roles in cancer prevention and treatment. He has personally treated over 3,000 patients with various types of cancer and performed over 10,000 surgical procedures.

Dr. Baskies received his Bachelor of Arts degree summa cum laude at Boston University, graduated from the Boston University School of Medicine, and completed his surgical residency at Boston Medical Center. He received his fellowship in surgical oncology at the National Cancer Institute.

What is Arnold M. Baskies' net worth?: The estimated net worth of Arnold M. Baskies is at least $2,398.00 as of March 15th, 2024. Dr. Baskies owns 110,000 shares of Baudax Bio stock worth more than $2,398 as of April 23rd. This net worth approximation does not reflect any other assets that Dr. Baskies may own. Learn More about Arnold M. Baskies' net worth.
How do I contact Arnold M. Baskies?: The corporate mailing address for Dr. Baskies and other Baudax Bio executives is 490 LAPP ROAD, MALVERN PA, 19355. Baudax Bio can also be reached via phone at 484-395-2440 and via email at [email protected]. Learn More on Arnold M. Baskies' contact information.
Has Arnold M. Baskies been buying or selling shares of Baudax Bio?: Arnold M. Baskies has not been actively trading shares of Baudax Bio during the past quarter. Most recently, on Tuesday, May 11th, Arnold M. Baskies bought 250 shares of Baudax Bio stock. The stock was acquired at an average cost of $32.80 per share, with a total value of $8,200.00. Following the completion of the transaction, the director now directly owns 2,161 shares of the company's stock, valued at $70,880.80. Learn More on Arnold M. Baskies' trading history.
Who are Baudax Bio's active insiders?: Baudax Bio's insider roster includes Arnold Baskies (Director), Richard Casten (CFO), Winston Churchill (Director), and Geraldine Henwood (CEO). Learn More on Baudax Bio's active insiders.

Arnold M. Baskies Insider Trading History at Baudax Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/11/2021	Buy	250	$32.80	$8,200.00	2,161

Arnold M. Baskies Buying and Selling Activity at Baudax Bio

Baudax Bio Company Overview

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

Today's Range

Now: $0.02

$0.02

50 Day Range

MA: $0.02

$0.02

$0.03

2 Week Range

Now: $0.02

$0.01

$3.47

Volume

310,800 shs

Average Volume

281,029 shs

Market Capitalization

$1.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57